syha 1801 | New Target Anti-tumor Drug “SYHA1801” Was Granted Clin

Keyword	CPC	PCC	Volume	Score	Length of keyword
syha 1801	1.73	0.5	4946	2	9
syha	0.2	1	8682	67	4
1801	1.99	0.3	1754	37	4

Keyword	CPC	PCC	Volume	Score
syha 1801	0.54	0.3	6809	80
syha 1813	1.4	0.4	561	17

Search Results related to syha 1801 on Search Engine

New Target Anti-tumor Drug “SYHA1801” Was Granted Clinical …
cmocro.com

https://www.cmocro.com/news_detail/New+Target+Anti-tumor+Drug+%26ldquo%3BSYHA1801%26rdquo%3B+Was+Grante/413118/index.html

WebAug 21, 2019 · New Target Anti-tumor Drug “SYHA1801” Was Granted Clinical Trial Approval - CMOCRO. NEWS DETAIL. Source : Press Release. Date : 2019-08-21. Event …

DA: 15 PA: 71 MOZ Rank: 44

The Novel RET Inhibitor SYHA1815 Inhibits RET-Driven Cancers …
aacrjournals.org

https://aacrjournals.org/mct/article/20/11/2198/673202/The-Novel-RET-Inhibitor-SYHA1815-Inhibits-RET

WebThe Novel RET Inhibitor SYHA1815 Inhibits RET-Driven Cancers and Overcomes Gatekeeper Mutations by Inducing G1 Cell-Cycle Arrest through c-Myc Downregulation | …

DA: 16 PA: 35 MOZ Rank: 94

Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) …
clinicaltrials.gov

https://classic.clinicaltrials.gov/ct2/show/NCT04309968

WebThis is a safety, pharmacokinetic and pharmacodynamic study designed to estimate the maximum tolerated dose (MTD), and determine the Recommended Phase 2 Dose … Allocation: Non-Randomized Intervention Model: Parallel Assignment Estimated Enrollment : 186 participants Study Type : Interventional (Clinical Trial)

Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Estimated Enrollment : 186 participants
Study Type : Interventional (Clinical Trial)

DA: 40 PA: 81 MOZ Rank: 41

A Study to Evaluate the Safety, Pharmacokinetics, and Anti …
clinicaltrials.gov

https://classic.clinicaltrials.gov/ct2/show/NCT06004245

WebAug 22, 2023 · This is a first-in-human, Phase I, open-label, multicenter, dose-escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, …

DA: 46 PA: 100 MOZ Rank: 40

Advanced Solid Tumors Trial in Tianjin (Drug: SYHA1801)
clincosm.com

https://www.clincosm.com/trial/advanced-solid-tumors-tianjin-drug-syha1801

WebJun 9, 2020 · Brief Summary. This is a safety, pharmacokinetic and pharmacodynamic study designed to estimate the maximum tolerated dose (MTD), and determine the …

DA: 55 PA: 23 MOZ Rank: 62

SYHA 1801 - AdisInsight
springer.com

https://adisinsight.springer.com/drugs/800057872

WebApr 25, 2023 · Request a free trial. SYHA 1801 is a small molecule inhibitor of bromodomain containing protein 4 (BRD4), being developed by CSPC ZhongQi Pharmaceutical …

DA: 52 PA: 36 MOZ Rank: 89

JPM | Free Full-Text | Integrating Genetic Alterations and …
mdpi.com

https://www.mdpi.com/2075-4426/12/10/1544

WebSep 20, 2022 · SYHA-1801: CSPC Pharmaceutical: BRD4: Phase I (NCT04309968) Solid, unspecified: JBI-802: Jubilant Life Sciences: LSD1: Phase II (NCT05268666) Solid, unspecified: seclidemstat: Salarius …

DA: 48 PA: 84 MOZ Rank: 11

Phase 1 study evaluating the safety, tolerability, pharmacokinetics …
ascopubs.org

https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.9112

WebMay 31, 2023 · Methods: This is a phase 1, open-label, multicenter study (CTR20212486) to evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of GEC255 in …

DA: 16 PA: 49 MOZ Rank: 21

| BioWorld
bioworld.com

https://www.bioworld.com/articles/677586-phase-i-study-of-brd4-inhibitor-syha-1801-begins-for-advanced-solid-tumors

WebPhase I study of BRD4 inhibitor SYHA-1801 begins for advanced solid tumors. May 12, 2020. No Comments. BioWorld Science Cancer. Popular Stories. Today's news in brief. …

DA: 74 PA: 63 MOZ Rank: 37

Ozmosi | SYHA-1801 Drug Profile
ozmosi.com

https://pryzm.ozmosi.com/product/syha-1801

WebSYHA-1801 Alternative Names: syha-1801, syha 1801, syha1801 Latest Update: 2020-06-09 Latest Update Note: Clinical Trial Update

DA: 4 PA: 74 MOZ Rank: 21